Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Adagio Medical Holdings ( (ADGM) ) has provided an announcement.
On April 8, 2026, Adagio Medical announced that the U.S. Food and Drug Administration granted Investigational Device Exemption approval to expand its FULCRUM-VT trial to study the next-generation vCLAS Ultra-Low Temperature Ablation Ventricular Ablation System in patients with sustained monomorphic ventricular tachycardia. The IDE expansion allows a prospective, single-arm, multi-center sub-study of up to 55 patients, aiming to validate a more efficient, versatile catheter that could shorten procedure times, improve manufacturability and scalability, and strengthen Adagio’s positioning in ventricular arrhythmia treatment.
The next-generation vCLAS Ultra catheter, built on Adagio’s established endocardial ULTA platform, is designed to reach approximately -170°C to enable single-freeze applications with markedly reduced ablation time, as demonstrated in pre-clinical models. Executives and investigators highlighted anticipated gains in energy delivery, navigation, lesion control, and workflow efficiency, underscoring the system’s potential to broaden adoption across electrophysiology practices and support deeper market penetration in treating scar-mediated ventricular tachycardia.
The most recent analyst rating on (ADGM) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Adagio Medical Holdings stock, see the ADGM Stock Forecast page.
Spark’s Take on ADGM Stock
According to Spark, TipRanks’ AI Analyst, ADGM is a Neutral.
The score is primarily constrained by weak financial performance: minimal/zero revenue, persistent losses, and ongoing negative free cash flow with elevated leverage. Technicals provide a partial offset with improving near-term momentum, but valuation is limited by negative earnings and no dividend support.
To see Spark’s full report on ADGM stock, click here.
More about Adagio Medical Holdings
Adagio Medical Holdings, Inc. is a medical device company specializing in catheter ablation technologies for the treatment of cardiac arrhythmias. The company focuses on its proprietary Ultra-Low Temperature Ablation platform and its purpose-built vCLAS cryoablation system, targeting ventricular arrhythmias and serving a largely underserved patient population in both U.S. and international markets.
Average Trading Volume: 54,907
Technical Sentiment Signal: Hold
Current Market Cap: $26.21M
See more insights into ADGM stock on TipRanks’ Stock Analysis page.